{
    "nctId": "NCT00847171",
    "briefTitle": "Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer",
    "officialTitle": "A Safety and Bioactivity Study of Combination Therapy With Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for the Treatment of Patients With High Risk/ Metastatic HER-2/Neu- Overexpressing Breast Cancer With No Evidence of Disease",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Safety as Assessed by Number of Participants Experiencing Toxicity",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast, meeting one of the following criteria:\n\n  * Metastatic disease\n  * High-risk disease, defined as early-stage disease with pathologic involvement of locoregional lymph nodes\n\n    * Patients who are/will be receiving standard adjuvant trastuzumab \\[Herceptin\u00ae\\] for high-risk disease will participate in this study during the single-agent trastuzumab portion of their therapy\n* No clinical or radiographical evidence of active disease\n* Not eligible for therapy of known curative potential for metastatic breast cancer\n* HER2/neu-overexpressing disease, defined as HER2/neu positive by IHC 3+ staining or by FISH+ amplification\n* Stable CNS disease allowed provided it has been adequately treated and is not under active treatment\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status 0-1\n* ANC \\> 1,000/mm\\^3\n* Platelet count \\> 100,000/mm\\^3\n* Serum creatinine \\< 2.0 mg/dL\n* Serum bilirubin \u2264 2.0 mg/dL (unless elevation is due to known Gilbert's syndrome)\n* AST/ALT \u2264 2 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 5 times ULN\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Cardiac ejection fraction normal by MUGA OR \u2265 45% by ECHO\n* No other malignancies within the past 5 years, except for carcinoma in situ of the cervix, superficial nonmelanoma skin cancer, or superficial bladder cancer\n* No prior or currently active autoimmune disease\\* requiring management with systemic immunosuppression, including any of the following:\n\n  * Inflammatory bowel disease\n  * Systemic vasculitis\n  * Scleroderma\n  * Psoriasis\n  * Multiple sclerosis\n  * Hemolytic anemia or immune-mediated thrombocytopenia\n  * Rheumatoid arthritis\n  * Systemic lupus erythematosus\n  * Sj\u00f6gren syndrome\n  * Sarcoidosis\n  * Other rheumatologic disease\n* No symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest\n* HIV-negative\n* No evidence of active acute or chronic infection\n* No uncontrolled medical problems\n* No active major medical or psychosocial problems that could be complicated by study participation\n* No corn allergy\n* No known severe hypersensitivity to trastuzumab (except for mild to moderate infusion reactions that are easily managed and do not recur) NOTE: \\*Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids allowed\n\nPRIOR CONCURRENT THERAPY:\n\n* Any number of prior chemotherapy regimens for metastatic breast cancer allowed\n* Prior or concurrent trastuzumab in the adjuvant or metastatic setting allowed\n* More than 28 days since prior and no concurrent systemic oral steroids\n\n  * Topical, ocular, or nasal steroids allowed\n* More than 28 days since prior and no concurrent chemotherapy, radiotherapy, or biologic therapy (except trastuzumab)\n* More than 28 days since prior and no concurrent participation in another investigational clinical trial involving a new drug\n* Concurrent endocrine therapy or bisphosphonates allowed",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}